Equities Analysts Issue Forecasts for Pharvaris Q3 Earnings

Pharvaris N.V. (NASDAQ:PHVS) – Wedbush boosted their Q3 2025 earnings per share (EPS) estimates for Pharvaris in a note issued to investors on Wednesday, August 13th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($0.77) per share for the quarter, up from their prior forecast of ($0.87). Wedbush has a “Outperform” rating and a $27.00 price objective on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. Wedbush also issued estimates for Pharvaris’ Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.49) EPS, Q1 2026 earnings at ($0.68) EPS, Q2 2026 earnings at ($0.69) EPS, Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($2.82) EPS, FY2027 earnings at ($1.65) EPS and FY2028 earnings at $0.73 EPS.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Tuesday, August 12th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.07).

Several other research analysts also recently issued reports on PHVS. JMP Securities lowered their price objective on Pharvaris from $55.00 to $52.00 and set a “market outperform” rating for the company in a research note on Wednesday. Cantor Fitzgerald lowered their price objective on Pharvaris from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, May 14th. Finally, Guggenheim assumed coverage on Pharvaris in a research note on Wednesday, June 11th. They issued a “buy” rating and a $32.00 price objective for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $35.60.

Pharvaris Price Performance

Pharvaris stock opened at $22.30 on Friday. The business has a 50 day moving average of $19.71 and a 200-day moving average of $17.24. Pharvaris has a 1 year low of $11.51 and a 1 year high of $26.33. The company has a market capitalization of $1.17 billion, a P/E ratio of -6.64 and a beta of -2.81.

Institutional Trading of Pharvaris

Several institutional investors have recently added to or reduced their stakes in the stock. Boothbay Fund Management LLC bought a new stake in Pharvaris in the second quarter valued at approximately $285,000. California State Teachers Retirement System boosted its holdings in Pharvaris by 9.8% in the second quarter. California State Teachers Retirement System now owns 14,048 shares of the company’s stock valued at $247,000 after acquiring an additional 1,257 shares during the last quarter. TFG Asset Management GP Ltd boosted its holdings in Pharvaris by 48.1% in the second quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company’s stock valued at $3,311,000 after acquiring an additional 61,105 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock valued at $860,000 after buying an additional 7,879 shares during the period. Finally, HighVista Strategies LLC lifted its stake in Pharvaris by 4.3% in the second quarter. HighVista Strategies LLC now owns 23,739 shares of the company’s stock valued at $418,000 after buying an additional 971 shares during the period.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.